

- OPTIMISED BIOAVAILABILITY • INCREASED STABILITY
- CLINICALLY PROVEN ABSORPTION

Supercharge bioavailability by over 600%

AquaCelle® Omega-3 is specifically designed to minimise fishy reflux and optimise the bioavailability of DHA and EPA, demonstrating increased absorption over 600% with supported evidence.

Award winning, developed and made in Australia.

AquaCelle® Omega-3 packs a punch with over 6x increased absorption, increased EPA and DHA uptake and reduced fishy burp-back. Leading the industry in dosage requirements and ease of incorporation into multi-active formulations.

INCREASED ABSORPTION

Studies have investigated technologies including nanoparticles, liposomes, emulsifying agents and other lipid-based delivery systems, however, there have been very few studies conducted in humans. AquaCelle® Omega-3 has undergone rigorous testing in human subjects that demonstrate an increased absorption of up to 600% over standard fish oil, dramatically improving omega-3 DHA and EPA uptake. When a small dose of omega-3s from krill oil combined with AquaCelle® (89 mg EPA+DHA) was compared against a much higher dose of EPA+DHA from fish oil (650 mg EPA+DHA), the AquaCelle® krill oil combination was found to be equivalent in absorption to the much higher fish oil dose.

IMPROVED FUNCTIONALITY

AquaCelle® effectively allows for smaller doses that boast enhanced bioavailability. The formulations deliver up to 85% concentrated omega-3 active load with a modest 15% AquaCelle® excipient. This industry leading ratio allows, for smaller and/or fewer doses, as well as offering ease of incorporation into multi-active formulations.

REDUCED REFLUX AND ODOUR


Fish and krill are the most significant sources of omega-3 fatty acids. AquaCelle® Omega-3 formulations have a unique ability to counteract the undesired "fishy" reflux, often associated with fish oil formulations, without enteric coating.



OPTIMISED BIOAVAILABILITY

Clinically proven to help the body achieve 6x better absorption of DHA + EPA than that of standard fish oil and better EPA + DHA absorption from AquaCelle® Krill compared to a 7x dose of fish oil.

Oral bioavailability over time



Formulating omega-3 ethyl ester with AquaCelle® demonstrated a significant improvement in the oral absorption of omega-3 fatty acids.

“The ever growing global omega-3 fatty acids market was estimated at USD 2.49 billion in 2019 and is expected to reach USD4.5 billion by 2027”

grandviewresearch.com

AquaCelle® Omega-3 advantages

- reduce dose size/number of capsules.
- increase absorption
- improve cost per dose
- overcome unpleasant side effects such as fishy reflux
- include oily actives in water-based and multi active formulations.
- optimised for stability
- no special manufacturing equipment required
- use your own omega-3 oil, fish krill or algal
- polysorbate free
- clinically proven with published studies and ongoing research.

AquaCelle® Omega-3 meets consumer needs such as:

- **Pill fatigue reduction:** “I want to take fewer and smaller pills.”
- **Sustainability:** “I don’t want to consume more than I need.”
- **Convenience:** “I forget to take my supplements with a fatty meal.”
- **No more fishy reflux:** “I’ll try it but if I experience unpleasant side effects I might stop.”
- **Health outcomes:** “Is this the best product I can take to reach my health goals.”
- **Water soluble oral liquid formulations.**
- **Multi-active formulations.**

Multi-award winning, supported by pharmacokinetic and clinical studies published in high impact journals, with a raft of continuing clinical studies under way.

- 1 PK Study – AquaCelle® Omega-3: A self-emulsifying omega-3 ethyl ester formulations AquaCelle® significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults.** Bremmell, K.E., Briskey, D., Meola, T.R. et al. Eur J Nutr 59, 2729–2737 (2020). doi.org/10.1007/s00394-019-02118-x
- 2 PK Study – Krill Oil: Analysis of AquaCelle® Krill Oil formulations versus various fish oil omega-3 results.** Briskey D, Rao A
- 3 PK Study – AquaCelle® Omega-3: The effect of dose and AquaCelle® on Omega-3 PUFAs absorbed from Algal Oil containing both EPA and DHA.** Briskey D, Rao A

AWARDS



ASIA
AquaCelle® Omega-3
Finalist Ingredient of the Year



AUSTRALIA
Quality Raw Material Supplier
of the Year 2021



USA
AquaCelle® Q₁₀
Healthy Ageing
Ingredient of the Year



ASIA
AquaCelle® Q₁₀
Healthy Ageing
Ingredient of the Year

EUROPE
AquaCelle®
Nutrition Research
of the Year



EUROPE
AquaCelle® Q₁₀
Healthy Ageing
Ingredient of the Year



AUSTRALIA
Quality Raw Material Supplier
of the Year 2018

Applying AquaCelle® trademarks on your product pack tells your customers you are offering a product of quality, proven efficacy, clinical validation and innovation.

FOR FURTHER INFORMATION ABOUT AQUACELLE® OMEGA-3
OR TO DISCUSS HOW AQUACELLE® OMEGA-3 CAN BENEFIT YOU, CONTACT:

pharmako.
BIOTECHNOLOGIES

Pharmako Biotechnologies
T +61 2 9451 0099
E enquiries@pharmako.com.au
W www.pharmako.com.au

AquaCelle® is a patented technology and a registered trade mark owned exclusively by Pharmako Biotechnologies Pty Ltd.

Please note this information is of an informative nature only, provided for customers globally and it may contain statements, claims or product classifications that do not comply with laws and regulations applicable to your country. The claims made are in reference to ingredients only, and not to finished products. You are responsible for all legal compliance for the finished products containing the ingredients and ensuring that the destination of the products and the claims made for them are lawful.